Oramed Pharmaceuticals Inc (ORMP) Stock AnalysisORMPStock AnalysisOramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Oramed Pharmaceuticals is a good buy right now due to its recent strong performance, including a 72.85% year-to-date change and a significant profit of $10 million in Q4 2026, which indicates growing profitability despite low revenue. The RSI is at 60.85, suggesting the stock is gaining momentum. However, the main risk is the high volatility indicated by an implied volatility of 300.1, which could lead to unpredictable price movements.

2 analysts cover ORMP: 2 rate it Buy, 0 Hold and 0 Sell.